FDA approves Aplenzin for depression treatment

Aplenzin (bupropion hydrobromide extended-release tablets, from Biovail) has been approved by the FDA for the treatment of depression in adults. Aplenzin is an alcohol-resistant formulation of the aminoketone, bupropion, and will be available in 174mg, 348mg, and 522mg dosage strengths.

For more information call (908) 927-1400 or visit www.biovail.com.